Applications of Cellular Systems Biology in Breast Cancer Patient Stratification and Diagnostics

Critchley-Thorne, Rebecca J.; Miller, Steven M.; Taylor, D. Lansing; Lingle, Wilma L.
November 2009
Combinatorial Chemistry & High Throughput Screening;Nov2009, Vol. 12 Issue 9, p860
Academic Journal
Tumors are complex structures of malignant cells and stromal cells that function as an integrated system that promotes tumor progression. Immune cells and other stromal components serve vital cooperative functions that often support tumor growth and metastasis; stromal content and function are strongly associated with disease progression and clinical outcome in cancer patients. Cellular systems biology considers tissues and tumors, and the cells within them, as integrated and interactive networks that function in concert as a system. Assessment of tumors as a "system" within the system of a patient using the cellular systems biology approach has the potential to improve on the current diagnostic tools for breast cancer by creating high content profiles of an individual patient's tumor. The application of cellular systems biology (CSBâ„¢) profiling to early drug discovery using cellular models of disease [1] and to drug development using the CellCiphrâ„¢ Cytotoxicity Profiling panels [2] can optimize the efficacy and decrease the potential toxicity of compounds taken into pre-clinical trials. However, it has become clear that patient sub-populations can respond differently to drug candidates in clinical trials due to patient variability. Therefore, cellular systems biology can also be a powerful approach to patient stratification for clinical trials and could become an important diagnostic tool. This review describes how the cellular systems biology approach can be applied to patient stratification and diagnostics in breast cancer, focusing on the advantages of quantifying functional biomarkers representing key tumor system processes in intact tissues from patients in order to make highly specific and sensitive predictions towards development of individualized medicine for breast cancer. We discuss the state-of-the-art of multiplexing of functional biomarkers in tissues and the practical utilization of the cellular systems biology approach in creating classifiers for patient stratification and diagnostics.


Related Articles

  • Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Yamaki, Sayaka; Fujii, Takaaki; Yajima, Reina; Hirakata, Tomoko; Yamaguchi, Satoru; Fujisawa, Tomomi; Tsutsumi, Soichi; Asao, Takayuki; Yanagita, Yasuhiro; Iijima, Misa; Kuwano, Hiroyuki // Surgery Today;Aug2013, Vol. 43 Issue 8, p901 

    Purpose: Galectin-3 expression is modulated in cancer cells, and that finding has led to the recognition of galectin-3 as a diagnostic or prognostic marker for various cancers, including breast cancer. This study investigated the correlation between galectin-3 expression and the...

  • Plasma MicroRNA Panel for Minimally Invasive Detection of Breast Cancer. Cuk, Katarina; Zucknick, Manuela; Madhavan, Dharanija; Schott, Sarah; Golatta, Michael; Heil, Jörg; Marmé, Frederik; Turchinovich, Andrey; Sinn, Peter; Sohn, Christof; Junkermann, Hans; Schneeweiss, Andreas; Burwinkel, Barbara // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Over the last few years, circulating microRNAs (miRNAs) have emerged as promising novel and minimally invasive markers for various diseases, including cancer. We already showed that certain miRNAs are deregulated in the plasma of breast cancer patients when compared to healthy women. Herein we...

  • Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Hoadley, Katherine A.; Siegel, Marni B.; Kanchi, Krishna L.; Miller, Christopher A.; Ding, Li; Zhao, Wei; He, Xiaping; Parker, Joel S.; Wendl, Michael C.; Fulton, Robert S.; Demeter, Ryan T.; Wilson, Richard K.; Carey, Lisa A.; Perou, Charles M.; Mardis, Elaine R. // PLoS Medicine;1/9/2017, Vol. 14 Issue 1, p1 

    [This corrects the article DOI: 10.1371/journal.pmed.1002174.].

  • Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism. Schoellhammer, Hans F.; Hsu, Felicia; Vito, Courtney; Peiguo Chu; Park, Jinha; Waisman, James; Kim, Joseph // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with systemic chemotherapy may lead to increased rates of pathologic...

  • Tumor Invasiveness, Not Lymphangiogenesis, Is Correlated with Lymph Node Metastasis and Unfavorable Prognosis in Young Breast Cancer Patients (≤35 Years). Zhang, Zhi-Qiang; Han, Yu-Zhen; Nian, Qing; Chen, Gang; Cui, Shu-Qing; Wang, Xing-Yong // PLoS ONE;12/11/2015, Vol. 10 Issue 12, p1 

    The morbidity rate of breast cancer is on the rise, and the age of onset appears to be trending toward a young age. Breast cancer in young women (BCYW) has a number of distinctive features that differ from breast cancer in middle-aged or elderly women (BCMEW). Lymphatic metastasis plays an...

  • Quantification of receptor-ligand binding with [F]fluciclatide in metastatic breast cancer patients. Tomasi, Giampaolo; Kenny, Laura; Mauri, Francesco; Turkheimer, Federico; Aboagye, Eric // European Journal of Nuclear Medicine & Molecular Imaging;Dec2011, Vol. 38 Issue 12, p2186 

    Purpose: The purpose of the study was to estimate the receptor-ligand binding of an arginine-glycine-aspartic acid (RGD) peptide in somatic tumours. To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the...

  • Benefits and Harms of Detecting Clinically Occult Breast Cancer. Amir, Eitan; Bedard, Philippe L.; Ocaña, Alberto; Seruga, Bostjan // JNCI: Journal of the National Cancer Institute;10/17/2012, Vol. 104 Issue 20, p1542 

    Over the last few decades there has been an increase in the use of strategies to detect clinically occult breast cancer with the aim of achieving diagnosis at an earlier stage when prognosis may be improved. Such strategies include screening mammography in healthy women, diagnostic imaging and...

  • Clinical and Ultrasonographic Characteristics of Breast Metastases from Extramammary Malignancies. Chun-Nan Yeh; Cheng-Hung Lin; Miin-Fu Chen // American Surgeon;Apr2004, Vol. 70 Issue 4, p287 

    Breast metastases from extramammary malignancies are uncommon, constituting about 2 per cent of all breast tumors. Breast metastasis may be confused with primary benign or malignant neoplasm of the breast. An accurate diagnosis of breast metastasis is important because the treatment and outcome...

  • Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Page, K.; Hava, N.; Ward, B.; Brown, J.; Guttery, D. S.; Ruangpratheep, C.; Blighe, K.; Sharma, A.; Walker, R. A.; Coombes, R. C.; Shaw, J. A. // British Journal of Cancer;4/12/2011, Vol. 104 Issue 8, p1342 

    Background:Human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in 20-25% of breast cancers. This study investigated circulating free DNA (cfDNA) for detection of HER2 gene amplification in patients with breast cancer.Methods:Circulating free DNA was extracted from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics